Location: Solmed Polyclinic (Zagreb)
Study Drug: Experimental biological therapy that modifies the function of B lymphocytes by affecting the enzymes BLyS and APRIL within the B lymphocytes, whose excessive activity causes increased secretion of immunoglobulins and their deposition in the kidneys.
Main Inclusion Criteria: Patients over 18 years old with a diagnosis of IgA nephropathy confirmed by biopsy at any time in the past, who have elevated proteins in 24-hour urine (>0.75 g/24h) but still maintain satisfactory kidney function (eGFR > 30 ml/min).
Status: In preparation
Start of patient enrollment: September 2024.
